Latest Conference Articles

Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.

As physicians treat more diverse patient populations, the importance of communicating properly with patients can have resounding effects on outcomes and adherence.

Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.

Both the intention-to-treat and on-treatment principles reported significant blood sugar reductions from the oral GLP-1 analogue.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

More people achieved weight reduction of ≥5% and ≥10% with semaglutide in all BMI subgroups.

The American Heart Association chief medical officer for prevention discussed the new ADA partnership and the new emphasis on comorbidity care.

The Healthy MOMs program resulted in positive improvements in diet and depressive symptoms for expecting Latinas, a population at a high risk for gestational and type 2 diabetes.

The Janssen product was found to be linked to a reduced risk of sustained kidney function loss, attenuated eFGR decline, and a reduction in albuminuria.

The investigative GLP-1 receptor agonist was compared to liraglutide, sitagliptin, and placebo in adult patients with type 2 diabetes.

Phase 1/2a clinical trial (NCT02253212) data on ultrasound-induced blood-brain barrier (BBB) opening for brain disorders like recurrent glioblastoma.

Iobenguane I 131 (AZEDRA) has been shown to be effective in patients with malignant, recurrent, or unresectable pheochromocytoma and paraganglioma (pheo/para).

The use of the maintenance regimen increased both 5-year disease-free survival (DFS) and 5-year overall survival (OS) in rhabdomyosarcoma.

Pauline Funchain MD, explains her research which focuses on assessing possible underlying genetic and familial factors in melanomas.

Radhakrishnan Ramchandren MD, highlights the recent US Food and Drug Administration’s (FDA) approval and advantages of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for advanced stage, classic Hodgkin lymphoma.

The phase 3 iNNOVATE trial finds ibrutinib in combination with rituximab to be safe and effective in relapsed/refractory and treatment-näive patients with Waldenström’s macroglobulinemia.

Researchers present promising phase 2 data regarding tazemetostat for malignant mesothelioma, the first reported clinical data of an EZH2 inhibitor in these patients.

Manuel Litchman, MD, President and CEO of Mustang Bio Inc, highlights the advantages of using CAR-T therapies as treatments for rare cancers.

E. Anders Kolb, MD, Director of Nemours Center for Cancer and Blood Disorders at Nemours/Alfred I. duPont Hospital for Children, explains the importance of teaching resiliency as an educational tool and addressing the psychosocial burdens placed on patients in pediatric oncology.

Researchers release updated data from the phase 3 ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell lung cancer.

Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, explains what a team approach should look like when treating brain tumors and other rare cancers.

Researchers find that the use of PET scans at baseline and after induction therapy can help them tailor chemotherapy regimens in esophageal cancer patients, increasing survival.

Owen A. O’Connor, MD, PhD, Director of Center for Lymphoid Malignancies at Columbia University, emphasizes the importance of sharing experiences among physicians and researchers in the rare diseases like peripheral T-cell lymphomas.

Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, discusses the importance of team approaches when treating brain tumors and other rare cancers.

Researchers report positive results for phase 1 trial of ivosidenib in patients with IDH1+ acute myeloid leukemia.

Results of a recent study demonstrate that treatment at a specialized cancer center is associated with better leukemia-specific survival in children, adolescents, and young adults.

A new phase 3 clinical trial boasts highest survival rates of these T-cell malignancies.

First-in-man phase 1 trial meets its primary endpoints by demonstrating safety and immunogenicity of a mutation-specific IDH1R132H peptide vaccine.